Eli Lilly and Seamless Therapeutics are teaming up to develop and commercialise programmable recombinase-based treatments targeting hearing loss indications, using Seamless’ proprietary recombinase platform.   The company’s technology performs large, precise DNA insertions in any target gene sequence, and operates independent of the cell’s natural DNA repair pathway.  Under the terms of the agreement, Seamless […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!